Incidence and Predictors of Myocardial Infarction After Transient Ischemic Attack
A Population-Based Study

Joseph D. Burns, MD; Alejandro A. Rabinstein, MD; Veronique L. Roger, MD, MPH; Latha G. Stead, MD; Teresa J.H. Christianson, BS; Jill M. Killian, BS; Robert D. Brown, Jr, MD, MPH

Background and Purpose—Coronary artery disease is the leading cause of death after TIA. Reliable estimates of the risk of MI after TIA, however, are lacking.

Methods—Our purpose was to determine the incidence of and risk factors for MI after TIA. We cross-referenced preexisting incidence cohorts from the Rochester Epidemiology Project for TIA (1985–1994) and MI (1979–2006) to identify all community residents with incident MI after incident TIA. Incidence of MI after TIA was determined using Kaplan–Meier life-table methods. This was compared to the age-, sex-, and period-specific MI incidences in the general population. Proportional hazards regression analysis was used to examine associations between clinical variables and the occurrence of MI after TIA.

Results—Average annual incidence of MI after TIA was 0.95%. Relative risk for incident MI in the TIA cohort compared to the general population was 2.09 (95% CI, 1.52–2.81). This was highest in patients younger than 60 years old (relative risk, 15.1; 95% CI, 4.11–38.6). Increasing age (hazard ratio, 1.51 per 10 years; 95% CI, 1.14–2.01), male sex (hazard ratio, 2.19; 95% CI, 1.18–4.06), and the use of lipid-lowering therapy at the time of TIA (hazard ratio, 3.10; 95% CI, 1.20–8.00) were independent risk factors for MI after TIA.

Conclusions—Average annual incidence of MI after TIA is approximately 1%, approximately double that of the general population. The relative risk increase is especially high in patients younger than 60 years old. These data are useful for identifying subgroups of patients with TIA at highest risk for subsequent MI. (Stroke. 2011;42:935-940.)

Key Words: incidence • risk factors • mortality • myocardial infarction • transient ischemic attack

Cerebral ischemia and coronary artery disease (CAD) are epidemiologically and pathophysiologically closely related diseases.³ It logically follows and has been empirically demonstrated that they often coexist in the same patient. In fact, CAD has been shown to be the leading cause of death in patients with TIA, causing more deaths than stroke. In 5 studies that have examined this topic, CAD has been responsible for 24% to 62% of deaths in the first 5 to 10 years after a TIA, whereas stroke accounted for 12% to 28%. In each study, fatal coronary events outnumbered fatal strokes by at least a factor of 2.²–⁶

Despite the key role played by CAD in the mortality of patients with TIA, reliable estimates of the risk of MI after TIA and the excess risk of MI in those who have had a TIA compared with the general population are lacking.³ Although a number of existing studies have examined the risk of MI in patients with TIA,³,⁵,⁷–¹⁰ these studies have many important limitations. These include the use of inexact definitions for CAD-related outcomes and the absence of risk factor analysis for the prediction of MI after TIA. In addition, only 1 study investigating this topic includes patients whose index TIA occurred after the 1980s.³ Only 2 of these studies have used a community-based approach, and neither of these used this design to estimate the difference in risk of MI between patients with TIA and the general population.⁷,⁹

We sought to improve on the existing knowledge about the risk of MI after TIA by performing a population-based study of events from a more recent time period using the resources of the Rochester Epidemiology Project.¹¹ This method minimizes selection and ascertainment biases and allows for estimation of the magnitude of the excess risk of MI in TIA patients compared to the general population.¹¹ Additionally, by using an extensive database of clinical variables defined using strict criteria and collected using a standardized protocol, we aimed to identify risk factors that mark those patients with TIA who are most likely to have MI. Finally,
we examined the role played by MI in the risk of death after TIA.

Subjects and Methods

Study Cohort

We studied a community-based cohort of patients with incident TIA that was identified retrospectively through the Rochester Epidemiology Project Medical Records Linkage System. This system has been described thoroughly elsewhere.13 Rochester, Minnesota is located in Olmsted County, where virtually all medical care is provided by 2 institutions, Mayo Medical Center and Olmsted Medical Center, with their affiliated outpatient, emergency, and inpatient sites. The medical record data for all care provided for Olmsted County residents at these 2 institutions as well as at medical practices in the surrounding communities, University of Minnesota-affiliated hospitals, and the Veterans’ Administration Hospital in Minneapolis, are recorded in a central computer index. This index is comprehensive, containing all inpatient and outpatient data, emergency department visits, nursing home care, and autopsy or death certificate information.

Using the Rochester Epidemiology Project, a cohort of Rochester residents who had incident TIA between the years 1985 and 1994 and a cohort of Olmsted County residents who had incident MI between 1979 and 2006 were identified. The procedures used to assemble these cohorts have been described in detail previously.12–14 Cases were initially identified from the medical record linkage system by a search using diagnostic codes. These diagnoses were then validated by chart review focusing on prespecified criteria performed by physicians and nurse abstractors using standardized protocols. This method of case ascertainment has been shown to be robust, providing results similar to a cohort approach.15 Finally, extensive data regarding potential risk factors for the diseases in question were obtained using standardized protocols and risk factor definitions.

The definition of TIA used in this study is the same as that used in an earlier study of this cohort by Brown et al.14 In brief, TIA was defined as an episode of focal neurological symptoms with abrupt onset and rapid resolution, lasting <24 hours, and caused by focal cerebral ischemia. Transient monocular blindness, which was included in the definition of TIA, was defined as an episode of transient monocular visual disturbance with abrupt onset and rapid resolution, lasting <24 hours, and caused by retinal ischemia. The diagnosis of TIA was made by a single senior stroke neurologist (R.D.B.) based on his review of detailed data from patients’ complete medical records. For any cases in which that senior stroke neurologist was uncertain of the diagnosis of TIA, the case was reviewed in detail by 2 other senior stroke neurologists. A final determination of TIA or no TIA was then made by consensus opinion of these 3. TIA etiology was classified as large-artery atherosclero-
sis, cardioembolic, lacunar, unknown, or other according to the classification scheme of the TOAST.16 Although the TOAST classification system is most commonly used in categorizing ischemic strokes, the subtype definitions readily apply to patients with TIA. The exception is the lacunar subtype, given that lacunar topography is of importance in its definition. For the TIA subtype categorization used in this study, patients with pure motor, pure sensory, or sensorimotor symptoms, which would otherwise fit the lacunar stroke criteria if they were longer in duration, were categorized as lacunar TIA.

Ascertainment of MI relied on epidemiological criteria combining cardiac pain, cardiac biomarkers, and electrocardiography. Details of this process, which have been shown to have excellent reliability, have been described in previous studies.13,17 The ascertainment of MI events in the Olmsted County population achieved by using this process is complete, as evidenced by the fact that MI rates determined by it are commensurate with MI rates in the other surveillance programs in the United States.18,19

We cross-referenced the TIA and MI cohorts to identify those Rochester residents who had an incident MI after incident TIA. In patients with incident MI that predated incident TIA, nonincident MI were identified using a method identical to that used to create the incident MI cohort. Using these methods, we identified Rochester residents who had MI through 2006 after an incident TIA that occurred during the years 1983 to 1994.

Statistical Methods

The incidence of MI after TIA was determined using Kaplan–Meier life-table methods. This was compared to the age-, sex-, and period-specific MI incidence in the general population of Olmsted County using a 1-sample log-rank test. The relative risk was calculated by dividing the number of observed MI by the expected number of MI over the duration of follow-up. CI were calculated according to the Poisson distribution. We used proportional hazards regression analysis to examine associations between clinical variables and the occurrence of MI after TIA and to examine the association between MI and death after TIA. Sex and those variables associated with an altered hazard ratio (HR) with \( P \leq 0.15 \) in the univariate analysis were entered into the multivariable predictive models. MI was analyzed as a time-dependent covariate in the mortality model. The correlation of the scaled Schoenfeld residuals with time was used to test the proportional hazards assumption. All proportional hazards assumptions were met for the survival free of MI. Antithrombotic treatment was associated with a greater reduced risk of death in the first 2 years after TIA. Because the covariate only had a slight nonproportionality and was not of primary interest, it was included as an adjustor in the mortality model. Analyses were performed using the statistical software package SAS version 8.2 (SAS Institute, Cary, NC).

Results

Cohort Characteristics

There were 456 incident TIA in Rochester residents between 1985 and 1994. Sixty-eight (15%) of these patients had a history of MI before TIA, of whom 8 (12%) had another MI after TIA. All subsequent results pertain to the 388 remaining patients who were at risk for incident MI after TIA. Follow-up data for this group were available for all but 1 patient through 5 years and was 98% and 72% complete at 10 and 20 years, respectively. For most patients with <20 years of follow-up, this was attributable to elapsed time limitations; only 15 patients were lost to follow-up (<4%) before the end of 2006 (the end of the MI data collection period).

Mean age at the time of TIA was 71±14 years and 41% of the patients were male (Table 1). Sixty-two percent had a history of hypertension, 11% had diabetes mellitus, and 55% were current or former smokers. Based on TOAST subtypes, 19% of the TIA were attributable to large artery atherosclerosis, 13% were cardioembolic, 6% were lacunar, and 5% were attributable to other causes. For 57% of the TIA, a single etiology could not be clearly established.

Occurrence of MI After TIA

Median duration of follow-up for the 388 patients who were at risk for incident MI after TIA was 10.2 years (range, 0–21.5 years). Forty-four of the patients in this group had MI after TIA, yielding an average annual incidence of MI after TIA of 0.95%. Median time from index TIA to index MI was 4.6 years (range, 0–20.6 years). Survival analysis shows that the risk of MI after
TIA remained essentially constant over time (Figure). The age-, sex-, and period-specific relative risk for incident MI in patients who had TIA, when compared to that of the general population, was 2.09 (95% CI, 1.52–2.81). This elevated risk was most pronounced in TIA patients younger than 60 years old, in whom the age-, sex-, and period-specific relative risk for MI was 15.1 (95% CI, 4.11–38.6) when compared to the general population. In comparison, for patients 60 years old and older, the age-, sex-, and period-specific relative risk for MI aggregated over 3 age groups (60–69 years, 70–79 years, and 80 years or older) was 1.93 (95% CI, 1.41–2.63) when compared to the general population.

### Predictors of MI After TIA

In the univariate proportional hazards analysis, increasing age and hypertension were associated with an increased risk of incident MI after TIA (Table 1). Use of lipid-lowering agents at the time of the TIA showed a trend toward association with an increased risk of MI after TIA ($P=0.06$). Multivariable analysis identified increasing age (HR, 1.51 per 10 years; 95% CI, 1.14–2.01), male sex (HR, 2.19; 95% CI, 1.18–4.06), and the use of lipid-lowering therapy at the time of TIA (HR, 3.10; 95% CI, 1.20–8.00) to be independent risk factors for MI after TIA (Table 2). This model, the association between hypertension and the risk of MI after TIA was no longer statistically significant (HR, 1.76; 95% CI, 0.90–3.45). TIA etiology was not a significant predictor of MI after TIA. This analysis was limited, however, by the fact that a single etiology could not be identified in many patients.

### Effect of MI on Mortality After TIA

Univariate analysis showed that patients who had MI after TIA were 3-times more likely to die during follow-up than those who did not have MI after TIA (HR, 2.19; 95% CI, 1.29–3.66). When adjusted for other factors found to be associated with mortality in this group (Table 3), MI remained a significant and substantial independent predictor of death after TIA (HR, 3.11; 95% CI, 2.11–4.57).

### Discussion

CAD is the leading cause of death in patients who have had TIA, and the 2 diseases have much in common epidemiologically.

#### Table 1. Patient Characteristics and Univariate Risk Factor Analysis for MI After TIA

<table>
<thead>
<tr>
<th>Variable</th>
<th>Total Study Population</th>
<th>No MI Before TIA</th>
<th>No Incident MI After TIA</th>
<th>Incident MI After TIA</th>
<th>Hazard Ratio (95% CI)</th>
<th>$P$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at index TIA (mean ± SD, years)</td>
<td>72 ± 14</td>
<td>71 ± 14</td>
<td>71 ± 15</td>
<td>72 ± 12</td>
<td>1.42 (1.10–1.83)$^*$</td>
<td>0.007</td>
</tr>
<tr>
<td>Male (%)</td>
<td>43</td>
<td>41</td>
<td>40</td>
<td>55</td>
<td>1.53 (0.84–2.77)</td>
<td>0.16</td>
</tr>
<tr>
<td>Hypertension (%)</td>
<td>64</td>
<td>62</td>
<td>61</td>
<td>70</td>
<td>2.02 (1.04–3.92)</td>
<td>0.04</td>
</tr>
<tr>
<td>Smoking (%)</td>
<td>55</td>
<td>55</td>
<td>54</td>
<td>57</td>
<td>0.91 (0.50–1.66)</td>
<td>0.75</td>
</tr>
<tr>
<td>Diabetes (%)</td>
<td>13</td>
<td>11</td>
<td>11</td>
<td>11</td>
<td>1.12 (0.40–3.14)</td>
<td>0.83</td>
</tr>
<tr>
<td>Lipid-lowering treatment (%)</td>
<td>5</td>
<td>5</td>
<td>4</td>
<td>11</td>
<td>2.42 (0.95–6.16)</td>
<td>0.06</td>
</tr>
<tr>
<td>Antithrombotic treatment (%)</td>
<td>75</td>
<td>84</td>
<td>83</td>
<td>88</td>
<td>1.25 (0.49–3.18)</td>
<td>0.64</td>
</tr>
<tr>
<td>TIA etiology subtype (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Large artery atherosclerosis</td>
<td>20</td>
<td>19</td>
<td>18</td>
<td>27</td>
<td>1.51 (0.78–2.93)</td>
<td>0.22</td>
</tr>
<tr>
<td>Cardioembolic</td>
<td>15</td>
<td>13</td>
<td>14</td>
<td>9</td>
<td>0.74 (0.26–2.08)</td>
<td>0.57</td>
</tr>
<tr>
<td>Lacunar</td>
<td>5</td>
<td>6</td>
<td>5</td>
<td>9</td>
<td>1.62 (0.58–4.54)</td>
<td>0.36</td>
</tr>
<tr>
<td>Unknown</td>
<td>55</td>
<td>57</td>
<td>58</td>
<td>48</td>
<td>0.67 (0.37–1.22)</td>
<td>0.19</td>
</tr>
<tr>
<td>Other</td>
<td>4</td>
<td>5</td>
<td>5</td>
<td>7</td>
<td>1.44 (0.45–4.68)</td>
<td>0.54</td>
</tr>
</tbody>
</table>

CI indicates confidence interval; MI, myocardial infarction; SD, standard deviation; TIA, transient ischemic attack.

*Hazard ratio is per 10 years.

#### Table 2. Multivariable Risk Factor Model for MI After TIA

<table>
<thead>
<tr>
<th>Variable</th>
<th>Hazard Ratio (95% CI)</th>
<th>$P$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (per 10 years)</td>
<td>1.51 (1.14–2.01)</td>
<td>0.004</td>
</tr>
<tr>
<td>Male</td>
<td>2.19 (1.18–4.06)</td>
<td>0.01</td>
</tr>
<tr>
<td>Hypertension</td>
<td>1.76 (0.90–3.45)</td>
<td>0.10</td>
</tr>
<tr>
<td>Lipid-lowering therapy</td>
<td>3.10 (1.20–8.00)</td>
<td>0.02</td>
</tr>
</tbody>
</table>

CI indicates confidence interval; MI, myocardial infarction; TIA, transient ischemic attack.
For Table 3. Multivariable Model for Risk of Mortality After TIA:

<table>
<thead>
<tr>
<th>Variable</th>
<th>Hazard Ratio (95% CI)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (per 10 years)</td>
<td>2.30 (2.00–2.63)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Male</td>
<td>1.05 (0.79–1.40)</td>
<td>0.72</td>
</tr>
<tr>
<td>Hypertension</td>
<td>1.28 (0.97–1.68)</td>
<td>0.08</td>
</tr>
<tr>
<td>Smoking</td>
<td>1.30 (0.98–1.73)</td>
<td>0.07</td>
</tr>
<tr>
<td>Diabetes</td>
<td>1.54 (1.05–2.23)</td>
<td>0.03</td>
</tr>
<tr>
<td>Antithrombotic treatment</td>
<td>0.67 (0.49–0.92)</td>
<td>0.01</td>
</tr>
<tr>
<td>Myocardial infarction after TIA</td>
<td>3.11 (2.11–4.57)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

CI indicates confidence interval; TIA, transient ischemic attack.

In multivariate analysis, we identified male sex, increasing age, and the use of lipid-lowering therapy as independent risk factors for MI, whereas TIA etiologic subtype and diabetes were not. Our findings regarding the risk conferred by age and sex are consistent with the current understanding of CAD risk factors and pathogenesis and are in agreement with the only other study that has examined this relationship. Although hypertension is an important risk factor for CAD, its role as a risk factor for MI after TIA is unclear from our data. Two factors could explain this. First, effective treatment of hypertension in our population could have obscured a difference in MI risk conferred by the disease. Second, a larger number of outcomes than the 44 MI encountered in our population may have been necessary to discern a statistically significant difference between those with and without hypertension. Similarly, despite the fact that both MI and large artery cerebral infarctions and TIA are caused by atherosclerosis, we did not find an association between any etiologic cerebral ischemia subtype and subsequent MI. This may have been because of the small number of outcome events (MI) in conjunction with relatively few patients within each etiologic subtype group. Finally, we found that the use of lipid-lowering therapy was an independent predictor of MI after TIA, perhaps because the use of such medications served as a surrogate marker for dyslipidemia and more severe athero-sclerosis. Unfortunately, data regarding specific serum lipid measurements were relatively incomplete in our population for this issue to be meaningfully investigated more directly.

In the population of patients with TIA we studied, having MI increased the risk of death by a factor of 3. Given that MI has been shown by many previous studies to be the major cause of death after TIA, this finding is not surprising. Nonetheless, it supports the concept of careful primary prevention of CAD in TIA patients, even in the absence of symptoms. It also suggests that screening for CAD in at least some TIA patients may be reasonable.

Strengths of this study include the population-based design, long and complete follow-up, standardized data collection techniques, and strict definitions for TIA, MI, and potential risk factors. Nonetheless, this study also has a number of limitations. First, racial and ethnic differences exist in the epidemiology of CAD and ischemic cerebrovascular disease. Because the population of Rochester is predominantly white, our findings might not be applicable to other racial and ethnic groups. Second, our community comparison population was matched for age, sex, and year of diagnosis, but not for other variables that
are known to affect the risk of MI. We therefore were not able to determine the amount of excess MI risk in our cohort caused by TIA alone. Third, insufficient data were available to optimally assess the effects of lipid and cholesterol disorders, key CAD risk factors, on the risk of MI after TIA. Fourth, the cohort size and number of events may limit power to detect risk factors for MI after TIA. Fifth, as indicated by higher point estimates for the incidence of TIA in persons aged 85 years or older in the Oxford Vascular Study data compared to our data, our case ascertainment for TIA may not have been complete in this age group.14,28 This may have led to under-representation of older people with TIA in our analysis. However, the overall completeness of ascertainment of TIA cases in our data is supported by an earlier study that demonstrated the equivalence of cohort and medical records linkage methods in TIA case ascertainment,13 as well as the comparable TIA incidence rates between the Rochester and Oxfordshire data for all other age groups. Finally, although more contemporary than that from most previously published studies, our study data are from a period that began >20 years ago. Because the incidence of MI has diminished since then,21–23 our data may overestimate the risk of MI in present-day patients.

Conclusions

In conclusion, this study shows that patients who have had TIA but do not have known CAD have approximately twice the risk for subsequent MI compared to the general population. This risk accumulates linearly over time for many years after the TIA, with an incidence of TIA after MI of ≈ 1% per year. Patients younger than 60 years old at the time of TIA may have an especially high age-adjusted risk for future MI. Given that CAD plays an important role in the mortality of patients after TIA, these data support the existing concept! that careful attention to the primary prevention of CAD is warranted in all patients who have had TIA and that screening for asymptomatic CAD may be useful in select TIA patients.

Sources of Funding

Supported by the Mayo Clinic and National Institutes of Health.

Disclosures

Burns was responsible for study conception and design, data acquisition, manuscript drafting, and critical review of manuscript. Rabinstein was responsible for study conception and design, study supervision, and critical review of manuscript. Roger was responsible for study conception and design, data acquisition, study supervision, and critical review of manuscript. Stead was responsible for critical review of manuscript. Christianson was responsible for data acquisition, statistical analysis, manuscript drafting, and critical review of manuscript. Killian was responsible for data acquisition and statistical analysis. Brown was responsible for study conception and design, funding and supervision, manuscript drafting, and critical review of manuscript. Burns is now affiliated with the Departments of Neurology and Neurosurgery, Boston University School of Medicine, Boston, Massachusetts. Stead is now affiliated with the Department of Emergency Medicine, University of Florida College of Medicine at Gainesville, Florida. Burns is a co-investigator in an investigator-initiated project with research funds provided by CardioNet. Rabinstein is a principal investigator in an investigator-initiated project with research funds provided by CardioNet.

References


Incidence and Predictors of Myocardial Infarction After Transient Ischemic Attack: A Population-Based Study

Stroke. 2011;42:935-940; originally published online March 24, 2011;
doi: 10.1161/STROKEAHA.110.593723
Stroke is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2011 American Heart Association, Inc. All rights reserved.
Print ISSN: 0039-2499. Online ISSN: 1524-4628

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://stroke.ahajournals.org/content/42/4/935

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Stroke can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Stroke is online at:
http://stroke.ahajournals.org/subscriptions/